Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system

International Journal of Cardiology

Volumn 245, Issue , 2017, Pages 277-284

  Nilsson, Erik ^a,b   Gasparini, Alessandro ^c   Ärnlöv, Johan ^d   Xu, Hairong ^e   Henriksson, Karin M ^d   Coresh, Josef ^f   Grams, Morgan E ^f   Carrero, Juan Jesus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e ASTRAZENECA   (United Kingdom)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Epidemiology; Hyperkalemia; Hypokalemia; Renin angiotensin aldosterone system inhibitors

Indexed keywords

POTASSIUM;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; EUROPE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RATING SCALE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE TONE; SWEDEN; BLOOD; HEALTH CARE DELIVERY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TRENDS;

ADULT; AGED; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; HYPERKALEMIA; HYPOKALEMIA; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SWEDEN;

EID: 85025455414     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.07.035     Document Type: Article

References (49)

1. Kovesdy, C.P., Management of hyperkalemia: an update for the internist. Am. J. Med. 128:12 (2015), 1281–1287.
2. Kovesdy, C.P., Updates in hyperkalemia: outcomes and therapeutic strategies. Rev. Endocr. Metab. Disord., September 2016, 1–7, 10.1007/s11154-016-9384-x.
3. Lazich, I., Bakris, G.L., Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin. Nephrol. 34:3 (2014), 333–339.
4. Salem, C.B., Badreddine, A., Fathallah, N., Slim, R., Hmouda, H., Drug-induced hyperkalemia. Drug Saf. 37:9 (2014), 677–692.
5. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341:10 (1999), 709–717.
6. Reardon, L.C., Macpherson, D.S., Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?. Arch. Intern. Med. 158:1 (1998), 26–32.
7. Epstein, M., Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int. Suppl. 6:1 (2016), 20–28.
8. Cooper, L.B., Hammill, B.G., Peterson, E.D., et al. Characterization of mineralocorticoid receptor antagonist therapy initiation in high-risk patients with heart failure. Circ. Cardiovasc. Qual. Outcomes, 10(1), 2017, 10.1161/CIRCOUTCOMES.116.002946.
9. Cooper, L.B., Hammill, B.G., Peterson, E.D., et al. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 314:18 (2015), 1973–1975.
10. Allen, L.A., Shetterly, S.M., Peterson, P.N., et al. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. Circ. Heart Fail. 7:1 (2014), 43–50.
11. Einhorn, L.M., Zhan, M., Hsu, V.D., et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med., 169(12), 2009, 1156.
12. Chang, A.R., Sang, Y., Leddy, J., et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 67:6 (2016), 1181–1188.
13. Runesson, B., Gasparini, A., Qureshi, A.R., et al. The Stockholm CREAtinine measurements (SCREAM) project: protocol overview and regional representativeness. Clin. Kidney J. 9:1 (2016), 119–127.
14. Rosén, M., National health data registers: a Nordic heritage to public health. Scand. J. Public Health 30:2 (2002), 81–85.
15. Wettermark, B., Hammar, N., Fored, C.M., et al. The new Swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol. Drug Saf. 16:7 (2007), 726–735.
16. Evans, M., Suttorp, M.M., Bellocco, R., et al. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol. Dial. Transplant. 31:4 (2016), 628–635.
17. Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150:9 (2009), 604–612.
18. Rustad, P., Felding, P., Franzson, L., et al. The Nordic reference interval project 2000: recommended reference intervals for 25 common biochemical properties. Scand. J. Clin. Lab. Invest. 64:4 (2004), 271–284.
19. Sarafidis, P.A., Blacklock, R., Wood, E., et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin. J. Am. Soc. Nephrol. 7:8 (2012), 1234–1241.
20. Hayes, J., Kalantar-Zadeh, K., Lu, J.L., Turban, S., Anderson, J.E., Kovesdy, C.P., Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin. Pract. 120:1 (2012), c8–16.
21. Jain, N., Kotla, S., Little, B.B., et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am. J. Cardiol. 109:10 (2012), 1510–1513.
22. Moranne, O., Froissart, M., Rossert, J., et al. Timing of onset of CKD-related metabolic complications. J. Am. Soc. Nephrol. 20:1 (2009), 164–171.
23. Weinberg, J.M., Appel, L.J., Bakris, G., et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch. Intern. Med. 169:17 (2009), 1587–1594.
24. Gasparini, A., Evans, M., Coresh, J., et al. Prevalence and recognition of chronic kidney disease in stockholm healthcare. Nephrol. Dial. Transplant. 31:12 (2016), 2086–2094.
25. Plantinga, L.C., Boulware, L.E., Coresh, J., et al. Patient awareness in chronic kidney disease: trends and predictors. Arch. Intern. Med. 168:20 (2008), 2268–2275.
26. Raebel, M.A., Smith, M.L., Saylor, G., et al. The positive predictive value of a hyperkalemia diagnosis in automated health care data. Pharmacoepidemiol. Drug Saf. 19:11 (2010), 1204–1208.
27. Fleet, J.L., Shariff, S.Z., Gandhi, S., Weir, M.A., Jain, A.K., Garg, A.X., Validity of the international classification of diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open, 2(6), 2012, e002011.
28. Choi, J.S., Kim, Y.A., Kim, H.Y., et al. Relation of serum potassium level to long-term outcomes in patients with acute myocardial infarction. Am. J. Cardiol. 113:8 (2014), 1285–1290.
29. Goyal, A., Spertus, J.A., Gosch, K., et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 307:2 (2012), 157–164.
30. Krogager, M.L., Torp-Pedersen, C., Mortensen, R.N., et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur. Heart J. 38:2 (2017), 104–112.
31. Tromp, J., ter Maaten, J.M., Damman, K., et al. Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials). Am. J. Cardiol. 119:2 (2017), 290–296.
32. Luo, J., Brunelli, S.M., Jensen, D.E., Yang, A., Association between serum potassium and outcomes in patients with reduced kidney function. Clin. J. Am. Soc. Nephrol. 11:1 (2016), 90–100.
33. Desai, A.S., Swedberg, K., McMurray, J.J., et al. Incidence and predictors of hyperkalemia in patients with heart failure. J. Am. Coll. Cardiol. 50:20 (2007), 1959–1966.
34. Takaichi, K., Takemoto, F., Ubara, Y., Mori, Y., Analysis of factors causing hyperkalemia. Intern. Med. 46:12 (2007), 823–829.
35. Espinel, E., Joven, J., Gil, I., et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Res. Notes, 6, 2013, 306.
36. McKelvie, R.S., Yusuf, S., Pericak, D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation 100:10 (1999), 1056–1064.
37. Pitt, B., Anker, S.D., Bushinsky, D.A., et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur. Heart J. 32:7 (2011), 820–828.
38. Buysse, J.M., Huang, I.-Z., Pitt, B., PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Futur. Cardiol. 8:1 (2012), 17–28.
39. Weir, M.R., Bakris, G.L., Bushinsky, D.A., et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N. Engl. J. Med. 372:3 (2015), 211–221.
40. Kosiborod, M., Rasmussen, H.S., Lavin, P., et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312:21 (2014), 2223–2233.
41. Bloomfield, R.L., Wilson, D.J., Buckalew, V.M., The incidence of diuretic-induced hypokalemia in two distinct clinic settings. J. Clin. Hypertens. 2:4 (1986), 331–338.
42. Gennari, F.J., Hypokalemia. N. Engl. J. Med. 339:7 (1998), 451–458.
43. Weiner, I.D., Wingo, C.S., Hypokalemia–consequences, causes, and correction. J. Am. Soc. Nephrol. 8:7 (1997), 1179–1188.
44. Paltiel, O., Salakhov, E., Ronen, I., Berg, D., Israeli, A., Management of severe hypokalemia in hospitalized patients: a study of quality of care based on computerized databases. Arch. Intern. Med. 161:8 (2001), 1089–1095.
45. Pepin, J., Shields, C., Advances in diagnosis and management of hypokalemic and hyperkalemic emergencies. Emerg. Med. Pract. 14:2 (2012), 1–17 (quiz 17–18).
46. Kim, H.-J., Han, S.-W., Therapeutic approach to hyperkalemia. Nephron 92:Suppl. 1 (2002), 33–40.
47. Jessup, M., Abraham, W.T., Casey, D.E., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation 119:14 (2009), 1977–2016.
48. McMurray, J., Cohen-Solal, A., Dietz, R., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur. J. Heart Fail. 7:5 (2005), 710–721.
49. Levin, A., Stevens, P.E., Bilous, R.W., et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3:1 (2013), 1–150.